Paper · 28210698

Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy.

Ono A and 21 others. Cell Mol Gastroenterol Hepatol, 2015. Cited by 86 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy. Papers, record 28210698. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28210698

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy.; PubMed
Journal: Cell Mol Gastroenterol Hepatol; PubMed
Year: 2015; PubMed
Publication types: Journal Article; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/28210698/; PubMed
DOI: https://doi.org/10.1016/j.jcmgh.2015.06.009; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC5301414/; PubMed
The journal: https://conductscience.org/library/journal-index/101648302; PubMed
Citations, by iCite: 86; iCite
Relative citation ratio, by iCite: 2.69; iCite
Revised in PubMed: 2019-11-20; PubMed

Authors22

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Ono A	Atsushi
2	Fujimoto A	Akihiro
3	Yamamoto Y	Yujiro
4	Akamatsu S	Sakura
5	Hiraga N	Nobuhiko
6	Imamura M	Michio
7	Kawaoka T	Tomokazu
8	Tsuge M	Masataka
9	Abe H	Hiromi
10	Hayes CN	C Nelson

1 to 10 of 22Source PubMed

See all 22 authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

Trial	Title	The trial lists it as	Named in the paper's record
NCT03956940	Analysis of cfDNA in Patients With Hepatocarcinoma and Treated by Sorafenib or Regorafenib	Background

Source ClinicalTrials.gov

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References37

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	21,374,666	Management of hepatocellular carcinoma: an update.	Hepatology	2011	https://conductscience.org/library/papers/21374666	PubMed
2	18,565,886	Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.	J Clin Oncol	2008	https://conductscience.org/library/papers/18565886	PubMed
3	21,562,580	Cell-free nucleic acids as biomarkers in cancer patients.	Nat Rev Cancer	2011	https://conductscience.org/library/papers/21562580	PubMed
4	23,634,288	Ultradeep sequencing detects GNAQ and GNA11 mutations in cell-free DNA from plasma of patients with uveal melanoma.	Cancer Med	2013	https://conductscience.org/library/papers/23634288	PubMed
5	18,670,422	Circulating mutant DNA to assess tumor dynamics.	Nat Med	2008	https://conductscience.org/library/papers/18670422	PubMed
6	24,007,628	Plasma is a better source of tumor-derived circulating cell-free DNA than serum for the detection of EGFR alterations in lung tumor patients.	Lung Cancer	2013	https://conductscience.org/library/papers/24007628	PubMed
7	23,182,627	Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.	Lancet Oncol	2013	https://conductscience.org/library/papers/23182627	PubMed
8	10,080,602	K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance.	J Clin Oncol	1999	https://conductscience.org/library/papers/10080602	PubMed
9	19,470,923	Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.	J Clin Oncol	2009	https://conductscience.org/library/papers/19470923	PubMed
10	19,541,911	Circos: an information aesthetic for comparative genomics.	Genome Res	2009	https://conductscience.org/library/papers/19541911	PubMed

1 to 10 of 37

See all 37 references

Cited by71

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 86 citations.

PMID	Title	Journal	Year	In Papers	Source
42,181,045	Advancements in cancer biomarker discovery over fifteen years: diagnostics and prognostic approach in somatic cancer.	Oncol Rev	2026	https://conductscience.org/library/papers/42181045	PubMed
42,137,650	Hepatic Artery Infusion Chemotherapy for Cholangiocarcinoma in 2025.	Liver Cancer	2026	https://conductscience.org/library/papers/42137650	PubMed
41,743,182	Correlation analysis between plasma circulating tumour deoxyribonucleic acid variations and survival in patients with hepatocellular carcinoma.	Front Oncol	2025	https://conductscience.org/library/papers/41743182	PubMed
40,936,747	Prognostic Significance of Liquid Biopsy-Detected Genetic Alterations in Hepatocellular Carcinoma.	J Hepatocell Carcinoma	2025	https://conductscience.org/library/papers/40936747	PubMed
40,699,663	Decoding Hepatocellular Carcinoma Metastasis: Molecular Mechanisms, Targeted Therapies, and Potential Biomarkers.	Curr Issues Mol Biol	2025	https://conductscience.org/library/papers/40699663	PubMed
40,563,578	Updates on Liquid Biopsy and ctDNA in Transplant Oncology.	Cancers (Basel)	2025	https://conductscience.org/library/papers/40563578	PubMed
40,343,687	Liquid Biopsy in Hepatocellular Carcinoma: ctDNA as a Potential Biomarker for Diagnosis and Prognosis.	Curr Oncol Rep	2025	https://conductscience.org/library/papers/40343687	PubMed
40,092,864	The ctDNA revolution: Insights on cancer care: A narrative review.	Bioinformation	2024	https://conductscience.org/library/papers/40092864	PubMed
40,059,633	Impact of Minimal Residual Disease on Early Recurrence of Liver Metastatic Colorectal Cancer.	Cancer Sci	2025	https://conductscience.org/library/papers/40059633	PubMed
39,719,624	Novel biomarkers for monitoring and management of hepatocellular carcinoma.	Cancer Cell Int	2024	https://conductscience.org/library/papers/39719624	PubMed

1 to 10 of 71

See all 71 cited by

Genes8

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes	Source
ACE	1,636	PubTator's text mining	https://conductscience.org/library/genes/1636	NCBI Gene
AFP	174	PubTator's text mining	https://conductscience.org/library/genes/174	NCBI Gene
EGFR	1,956	PubTator's text mining	https://conductscience.org/library/genes/1956	NCBI Gene
GNAS	2,778	PubTator's text mining	https://conductscience.org/library/genes/2778	NCBI Gene
GPT	2,875	PubTator's text mining	https://conductscience.org/library/genes/2875	NCBI Gene
KIT	3,815	PubTator's text mining	https://conductscience.org/library/genes/3815	NCBI Gene
KRAS	3,845	PubTator's text mining	https://conductscience.org/library/genes/3845	NCBI Gene
TXK	7,294	PubTator's text mining	https://conductscience.org/library/genes/7294	NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28210698

GET https://conductscience.org/api/papers/v1/28210698/authors?page=2

API reference For AI assistants